Cefuroxime combats endophthalmitis

Article

It is possible to achieve a lower rate of endophthalmitis with a single injection of cefuroxime at the conclusion of cataract surgery than by using the more traditional subconjunctival/topical regimens, according to Per Montan of the St Erik Eye Hospital, Stockholm, Sweden.

It is possible to achieve a lower rate of endophthalmitis with a single injection of cefuroxime at the conclusion of cataract surgery than by using the more traditional subconjunctival/topical regimens, according to Per Montan of the St Erik Eye Hospital, Stockholm, Sweden.

In 1996, St Erik's analysed the resistance patterns of 55 causative bacteria and found that 51 of these were sensitive to cefuroxime, a second-generation cephalosporin. It was decided to use 1 mg cefuroxime as a bolus injection at the conclusion of cataract extraction. A sharp decline in endophthalmitis was soon noticed and furthermore, the antibiotic proved to be safe in analyses of endothelial cell counts, laser flare measurements and the presence of IgE production.

Nationwide data confirmed these findings and now, 99% of cataract procedures are performed with intracameral cefuroxime. The incidence of endophthalmitis during the period between 2002 and 2004, based on a sample of 224,000 operations, is just 0.04%. For comparison purposes, data collected between 1999 and 2001, showed that, of the 6,800 procedures performed using topical or subconjunctival antibiotics, the incidence of endophthalmitis was 0.22% compared with 0.05% in the 153,000 operations using cefuroxime.

Montan concluded that it is entirely possible to achieve significantly lower rates of endophthalmitis by using cefuroxime than by using more traditional combined regimens.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.